Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Celecoxib on QT/QTc Interval in Healthy Volunteers
NCT03822520Phase 1Completed
- Sponsor
- Samsung Medical Center
- Start
- Jun 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of celecoxib oral solution in osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS) and 2 more (4 arms), sponsored by Samsung Medical Center. Primary endpoint: Change in QTc interval, read manually. Started Jun 2017; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)ankylosing spondylitis (AS)acute painprimary dysmenorrhea (PD)
Beyond the preview
Go deeper on NCT03822520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822520.